Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study
- 1Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK
- 2Photobiology Unit, Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Abstract
Afamelanotide, an analogue of α-melanocyte stimulating hormone, activates the melanocortin-1 receptor and has a range of protective properties as demonstrated largely in vitro. While afamelanotide is approved to treat a visible light-induced inflammatory dermatosis, erythropoetic protoporphyria, its acute effects in vivo are poorly characterised. We explored short-term effects of afamelanotide on the acute inflammatory response of UVR-induced erythema and on the melanogenic response, in healthy humans. Participants (n = 9, 5 M:4 F, 27-43y, phototypes II-III) had melanin density and skin lightness measured at six skin sites using spectrophotometry. A broadband UVB dose-series (7–80 mJ/cm2 erythemally-weighted UVR, Philips TL12) was applied to buttock skin. After 24 h, minimal erythema dose (MED) was assessed, spectrophotometric measurements were taken of erythema at each dose site and two unexposed sites, and an unexposed site was biopsied. Afamelanotide was administered (16 mg subcutaneous implant) and after six days the same UVR dose-series applied to contralateral buttock skin, and measurements and biopsy repeated. Melanin was stained in biopsy sections (modified Warthin-Starry method) and quantified by image analysis. The UVR-erythema dose response (area-under-curve) decreased post-afamelanotide (mean 3.5 pre, 2.7 post, P = 0.018) with an apparent increase in MED (median 21 mJ/cm2 pre, 29.9 post, not sign.). Melanin density (reflectance at 420 and 400 nm) increased (mean overall increase 2.4% to 2.9%, P = 0.001), while melanin staining was unaltered. The demonstrated protection against acute UVR-induced erythema shortly after afamelanotide application supports that anti-inflammatory effects observed in vitro may operate in vivo, warranting further investigation in acute UVR-induced inflammatory conditions.
Graphical abstract:
Related
- Optimized Cardiorespiratory State at Tone Onset Enhances Sensory Responses but Not Associative Learning in Healthy Adults
- Deep TMS modulates neurovascular responses and enhances dual-task computation in healthy adults
- A randomised, placebo-controlled study to assess whether antibiotic-mediated disruption of the gut microbiota impairs BCG-induced specific and non-specific immunity in young, healthy adults: protocol for the Antibiotics and Vaccine Immune Responses Study (AVIRS).
- Atypical T cell receptor signalling permits distinct gut gd T cell responses to healthy versus dysregulated tissues
- Antibacterial, Anti-Inflammatory and Anti-Melanogenic Effects of a Novel Peptide.
BibTeX
@article{griffin2026acute,
title = {{Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study}},
author = {Liezel L. Griffin and Orsolya Kiss and Poonam Halai and Abigail K. Langton and Lesley E. Rhodes and Mark D. Farrar},
journal = {Photochemical \& Photobiological Sciences},
year = {2026},
month = sep,
doi = {10.1007/s43630-026-00986-x},
url = {https://doi.org/10.1007/s43630-026-00986-x},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study
AU - Liezel L. Griffin
AU - Orsolya Kiss
AU - Poonam Halai
AU - Abigail K. Langton
AU - Lesley E. Rhodes
AU - Mark D. Farrar
PY - 2026
DA - 2026/09/01
JO - Photochemical & Photobiological Sciences
DO - 10.1007/s43630-026-00986-x
UR - https://doi.org/10.1007/s43630-026-00986-x
AB - Afamelanotide, an analogue of α-melanocyte stimulating hormone, activates the melanocortin-1 receptor and has a range of protective properties as demonstrated largely in vitro. While afamelanotide is approved to treat a visible light-induced inflammatory dermatosis, erythropoetic protoporphyria, its acute effects in vivo are poorly characterised. We explored short-term effects of afamelanotide on the acute inflammatory response of UVR-induced erythema and on the melanogenic response, in healthy humans. Participants (n = 9, 5 M:4 F, 27-43y, phototypes II-III) had melanin density and skin lightness measured at six skin sites using spectrophotometry. A broadband UVB dose-series (7–80 mJ/cm2 erythemally-weighted UVR, Philips TL12) was applied to buttock skin. After 24 h, minimal erythema dose (MED) was assessed, spectrophotometric measurements were taken of erythema at each dose site and two unexposed sites, and an unexposed site was biopsied. Afamelanotide was administered (16 mg subcutaneous implant) and after six days the same UVR dose-series applied to contralateral buttock skin, and measurements and biopsy repeated. Melanin was stained in biopsy sections (modified Warthin-Starry method) and quantified by image analysis. The UVR-erythema dose response (area-under-curve) decreased post-afamelanotide (mean 3.5 pre, 2.7 post, P = 0.018) with an apparent increase in MED (median 21 mJ/cm2 pre, 29.9 post, not sign.). Melanin density (reflectance at 420 and 400 nm) increased (mean overall increase 2.4% to 2.9%, P = 0.001), while melanin staining was unaltered. The demonstrated protection against acute UVR-induced erythema shortly after afamelanotide application supports that anti-inflammatory effects observed in vitro may operate in vivo, warranting further investigation in acute UVR-induced inflammatory conditions. Graphical abstract:
SN - 1474-905X
SN - 1474-9092
ER -